Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Ali, DS; Khan, AA; Morrison, A; Tetradis, S; Mirza, RD; El, Rabbany, M; Abrahamsen, B; Aghaloo, TL; Al-Alwani, H; Al-Dabagh, R; Anastasilakis, AD; Bhandari, M; Body, JJ; Brandi, ML; Brignardello-Petersen, R; Brown, JP; Cheung, AM; Compston, J; Cooper, C; Diez-Perez, A; Ferrari, SL; Guyatt, G; Hanley, D; Harvey, NC; Josse, RG; Kendler, DL; Khan, S; Kim, S; Langdahl, BL; Magopoulos, C; Masri, BK; Morgan, SL; Morin, SN; Napoli, N; Obermayer-Pietsch, B; Palermo, A; Pepe, J; Peters, E; Pierroz, DD; Rizzoli, R; Saunders, DP; Stanford, CM; Sulimani, R; Taguchi, A; Tanaka, S; Watts, NB; Zamudio, J; Zillikens, MC; Ruggiero, SL.
Antiresorptive Therapy to Reduce Fracture Risk and Effects on Dental Implant Outcomes in Patients With Osteoporosis: A Systematic Review and Osteonecrosis of the Jaw Taskforce Consensus Statement.
Endocr Pract. 2025; 31(5):686-698
Doi: 10.1016/j.eprac.2025.02.016
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Obermayer-Pietsch Barbara
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- OBJECTIVE: Placement of a dental implant in a patient on antiresorptive therapy has been hypothesized to increase the risk of medication-related osteonecrosis of the jaw (MRONJ) and/or impact implant survival. In patients with osteoporosis, the risk of MRONJ with antiresorptive therapy is only marginally higher than observed in the general population. METHODS: The International ONJ Taskforce conducted a systematic review of the literature and evaluated the outcomes of implant placement in individuals with osteoporosis receiving antiresorptive therapy. RESULTS: The data were reviewed by the International Taskforce, and consensus was achieved on the following GRADEd recommendation. In patients with osteoporosis on antiresorptive therapy, the Taskforce suggests that antiresorptive therapy does not need to be stopped prior to proceeding with dental implant (weak recommendation, very low-quality evidence). Long-term bisphosphonate use maybe associated with a small increase in the risk of MRONJ (3 cases per 1000 patients; adjusted hazard ratio: 4.09, 95% CI: 2.75-6.09, P < .001, moderate certainty). CONCLUSION: Current evidence does not suggest an association between antiresorptive therapy in patients with osteoporosis and dental implant failure. Implants may be safely placed in the presence of concomitant use of bisphosphonates or denosumab in patients with osteoporosis with no evidence of an increased risk of implant failure/compromise.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Osteoporosis - drug therapy, complications
- Bone Density Conservation Agents - therapeutic use, adverse effects
- Dental Implants - adverse effects
- Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology, epidemiology
- Consensus - administration & dosage
- Diphosphonates - therapeutic use, adverse effects
- Find related publications in this database (Keywords)
- dental implants
- antiresorptive therapy
- osteoporosis
- osteonecrosis of the jaw
- MRONJ